Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Qi, Wentao ^a   Weber, Christopher R ^b   Wasland, Kaarin ^a   Savkovic, Suzana D ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Colon Cancer; EGF; FOXO3; Genistein; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR; GENISTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR FKHRL1; ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MUTANT PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG MECHANISM; GENE ACTIVITY; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; WILD TYPE; CELL PROLIFERATION; CELL STRAIN HCT116; CELL STRAIN HT29; COLON TUMOR; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; INTRACELLULAR SPACE; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EPIDERMAL GROWTH FACTOR; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HCT116 CELLS; HT29 CELLS; HUMANS; INTRACELLULAR SPACE; MUTANT PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957844724     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-219     Document Type: Article

References (50)

1. Adlercreutz CH, Goldin BR, Gorbach SL, Hockerstedt KA, Watanabe S, Hamalainen EK, Markkanen MH, Makela TH, Wahala KT, Adlercreutz T. Soybean phytoestrogen intake and cancer risk. The Journal of Nutrition 1995, 125(3 Suppl):757S-770S.
2. Park OJ, Surh YJ. Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicology Letters 2004, 150(1):43-56. 10.1016/j.toxlet.2003.06.001, 15068824.
3. Wang HK. The therapeutic potential of flavonoids. Expert Opinion on Investigational Drugs 2000, 9(9):2103-2119. 10.1517/13543784.9.9.2103, 11060796.
4. Barnes S, Peterson TG. Biochemical targets of the isoflavone genistein in tumor cell lines. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY 1995, 208(1):103-108.
5. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Investigation 2003, 21(5):744-757. 10.1081/CNV-120023773, 14628433.
6. Georgaki S, Skopeliti M, Tsiatas M, Nicolaou KA, Ioannou K, Husband A, Bamias A, Dimopoulos MA, Constantinou AI, Tsitsilonis OE. Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. Journal of Cellular and Molecular Medicine 2009, 13(9B):3929-3938. 10.1111/j.1582-4934.2009.00695.x, 19220577.
7. Zhu Q, Meisinger J, Van Thiel DH, Zhang Y, Mobarhan S. Effects of soybean extract on morphology and survival of Caco-2, SW620, and HT-29 cells. Nutrition and Cancer 2002, 42(1):131-140. 10.1207/S15327914NC421_18, 12235645.
8. Chodon D, Ramamurty N, Sakthisekaran D. Preliminary studies on induction of apoptosis by genistein on HepG2 cell line. Toxicol In Vitro 2007, 21(5):887-891. 10.1016/j.tiv.2007.01.023, 17391909.
9. Su SJ, Chow NH, Kung ML, Hung TC, Chang KL. Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity. Nutrition and Cancer 2003, 45(1):113-123. 10.1207/S15327914NC4501_13, 12791511.
10. Cantley LC. The phosphoinositide 3-kinase pathway. Science (New York, NY 2002, 296(5573):1655-1657.
11. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Current Opinion in Oncology 2006, 18(1):77-82. 10.1097/01.cco.0000198021.99347.b9, 16357568.
12. Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Science 2004, 95(6):475-480. 10.1111/j.1349-7006.2004.tb03235.x, 15182426.
13. Wang Z, Chen H. Genistein increases gene expression by demethylation of WNT5a promoter in colon cancer cell line SW1116. Anticancer Research 2010, 30(11):4537-4545.
14. Bielecki A, Roberts J, Mehta R, Raju J. Estrogen receptor-beta mediates the inhibition of DLD-1 human colon adenocarcinoma cells by soy isoflavones. Nutrition and Cancer 2011, 63(1):139-150.
15. Berner C, Aumuller E, Gnauck A, Nestelberger M, Just A, Haslberger AG. Epigenetic control of estrogen receptor expression and tumor suppressor genes is modulated by bioactive food compounds. Annals of Nutrition & Metabolism 2011, 57(3-4):183-189.
16. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. British Journal of Cancer 2010, 102(1):165-172. 10.1038/sj.bjc.6605473, 2813748, 19997103.
17. Fichera A, Little N, Jagadeeswaran S, Dougherty U, Sehdev A, Mustafi R, Cerda S, Yuan W, Khare S, Tretiakova M, Gong C, Tallerico M, Cohen G, Joseph L, Hart J, Turner JR, Bissonnette M. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Research 2007, 67(2):827-835. 10.1158/0008-5472.CAN-05-3343, 2705749, 17234795.
18. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anti-cancer Drugs 2009, 20(10):851-855. 10.1097/CAD.0b013e3283330590, 19826350.
19. Qi W, Weber CR, Wasland K, Roy H, Wali R, Joshi S, Savkovic SD. Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. American Journal of Physiology - Gastrointestinal and Liver Physiology 2011, 300(2):G264-272. 10.1152/ajpgi.00416.2010, 21109589.
20. Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochemical Science 2002, 27(7):352-360.
21. Nakamura Y, Yogosawa S, Izutani Y, Watanabe H, Otsuji E, Sakai T. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Molecular Cancer 2009, 8:100. 10.1186/1476-4598-8-100, 2784428, 19909554.
22. Yu Z, Li W, Liu F. Inhibition of proliferation and induction of apoptosis by genistein in colon cancer HT-29 cells. Cancer Letters 2004, 215(2):159-166. 10.1016/j.canlet.2004.06.010, 15488634.
23. Snoeks L, Weber CR, Turner JR, Bhattacharyya M, Wasland K, Savkovic SD. Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells. Infection and Immunity 2008, 76(10):4677-4685. 10.1128/IAI.00227-08, 2546851, 18678662.
24. Snoeks L, Weber CR, Wasland K, Turner JR, Vainder C, Qi W, Savkovic SD. Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation. Laboratory Investigation 2009, 89(9):1053-1062. 10.1038/labinvest.2009.66, 3048782, 19636295.
25. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA: A Cancer Journal for Clinicians 2007, 57(5):260-277.
26. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Majid S, Igawa M, Dahiya R. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. International Journal of Cancer 2008, 123(3):552-560.
27. Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, Hirata H, Li LC, Zhao H, Okino ST, Place RF, Pookot D, Dahiya R. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Research 2008, 68(8):2736-2744. 10.1158/0008-5472.CAN-07-2290, 18413741.
28. Lian F, Li Y, Bhuiyan M, Sarkar FH. p53-independent apoptosis induced by genistein in lung cancer cells. Nutrition and Cancer 1999, 33(2):125-131. 10.1207/S15327914NC330202, 10368806.
29. Wang F, Marshall CB, Yamamoto K, Li GY, Plevin MJ, You H, Mak TW, Ikura M. Biochemical and structural characterization of an intramolecular interaction in FOXO3a and its binding with p53. Journal of Molecular Biology 2008, 384(3):590-603. 10.1016/j.jmb.2008.09.025, 18824006.
30. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 mutations in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 1990, 87(19):7555-7559. 10.1073/pnas.87.19.7555, 54786, 1699228.
31. Rand A, Glenn KS, Alvares CP, White MB, Thibodeau SM, Karnes WE. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles. Cancer Letters 1996, 98(2):183-191.
32. Jaiswal AS, Narayan S. p53-dependent transcriptional regulation of the APC promoter in colon cancer cells treated with DNA alkylating agents. The Journal of Biological Chemistry 2001, 276(21):18193-18199. 10.1074/jbc.M101298200, 11279192.
33. Gerdes H. Colon cancer and the p53 oncogene. Gastroenterology 1991, 100(3):842-843.
34. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Molecular and Cellular Biology 1992, 12(6):2866-2871. 364481, 1588974.
35. Kwon TK, Nagel JE, Buchholz MA, Nordin AA. Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. Gene 1996, 180(1-2):113-120. 10.1016/S0378-1119(96)00416-7, 8973354.
36. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Molecular and Cellular Biology 2000, 20(24):9138-9148. 10.1128/MCB.20.24.9138-9148.2000, 102172, 11094066.
37. Dalu A, Haskell JF, Coward L, Lamartiniere CA. Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. The Prostate 1998, 37(1):36-43. 10.1002/(SICI)1097-0045(19980915)37:1<36::AID-PROS6>3.0.CO;2-6, 9721067.
38. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. The Journal of Biological Chemistry 1987, 262(12):5592-5595.
39. Rajah TT, Du N, Drews N, Cohn R. Genistein in the presence of 17beta-estradiol inhibits proliferation of ERbeta breast cancer cells. Pharmacology 2009, 84(2):68-73. 10.1159/000226123, 19556829.
40. Kim EJ, Shin HK, Park JH. Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. Journal of Medicinal Food 2005, 8(4):431-438. 10.1089/jmf.2005.8.431, 16379552.
41. Sheng H, Shao J, Townsend CM, Evers BM. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut 2003, 52(10):1472-1478. 10.1136/gut.52.10.1472, 1773820, 12970141.
42. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404(6779):782-787. 10.1038/35008115, 10783894.
43. Eto I. Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells. Cancer Cell International 2006, 6:20. 10.1186/1475-2867-6-20, 1559648, 16899133.
44. Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S, Hursting SD. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Molecular Carcinogenesis 2000, 29(2):92-102. 10.1002/1098-2744(200010)29:2<92::AID-MC6>3.0.CO;2-Q, 11074606.
45. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of EGF domains for ErbB receptors. FEBS Letters 1999, 447(2-3):227-231. 10.1016/S0014-5793(99)00283-5, 10214951.
46. You H, Yamamoto K, Mak TW. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(24):9051-9056. 10.1073/pnas.0600889103, 1482564, 16757565.
47. Miyaguchi Y, Tsuchiya K, Sakamoto K. P53 negatively regulates the transcriptional activity of FOXO3a under oxidative stress. Cell Biology International 2009, 33(8):853-860. 10.1016/j.cellbi.2009.04.017, 19427386.
48. Park JH, Oh EJ, Choi YH, Kang CD, Kang HS, Kim DK, Kang KI, Yoo MA. Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells. International Journal of Oncology 2001, 18(5):997-1002.
49. Weber G, Shen F, Yang H, Prajda N, Li W. Amplification of signal transduction capacity and down-regulation by drugs. Advances in Enzyme Regulation 1999, 39:51-66. 10.1016/S0065-2571(98)00027-2, 10470366.
50. Hwang JT, Ha J, Park OJ. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochemical and Biophysical Research Communications 2005, 332(2):433-440. 10.1016/j.bbrc.2005.04.143, 15896711.